Hansa Biopharma appoints Dr Hitto Kaufmann as chief scientific officer

Hansa Biopharma has announced the appointment of Dr Hitto Kaufmann as its new chief scientific officer effective 1 December 2023.
In his new role as CSO Kaufmann will be responsible for research, early development, translational and manufacturing activities, reporting to the company’s president and chief executive officer, Søren Tulstrup.
Previously, Kaufmann worked as CSO of Pieris Pharmaceuticals, leading its R&D platform developing innovative next generation protein therapeutics leading to several regulatory submissions.
Søren Tulstrup, president and CEO of Hansa Biopharma, commented: “We are thrilled to welcome Hitto to Hansa at this pivotal time. With over 20 years’ experience in research, development and advancement of science, he is poised to lead the development of our scientific platform and advancement of our pipeline of exciting drug candidates for rare immunologic diseases and conditions. Hitto has a proven track record of developing innovative medicines, advancing strategic R&D partnerships and building next generation therapeutic platforms. He has previously demonstrated an ability to build and lead high-performing teams in both large pharma and small biotech organisations.”
Hitto Kaufmann, added: “I am thrilled to build on the great work that has positioned Hansa as one of the most promising mid-stage biotech companies. Hansa has cutting-edge science – specifically its unique versatile IgG antibody cleaving enzyme platform – that will help deliver better patient outcomes in areas of high unmet need. I look forward to joining a team of diverse, talented people and to working across the company to develop and deliver life-saving and life-altering medicines.”